ATXI Share Price | Avenue Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Avenue Therapeutics, Inc.?

Market Cap: As of Jun 18, Avenue Therapeutics, Inc. has a market capitalization of 0.83 million, classifying it as a Micro Cap.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -13.71 million.Balance Sheet Snapshot: As of December 2024, Avenue Therapeutics, Inc. has shareholder's funds amounting to 2.80 million and total assets of 2.67 million.

Q: What does Avenue Therapeutics, Inc. do?

Overview: Avenue Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing intravenous (IV) Tramadol for the treatment of moderate to moderately severe post-operative pain, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 0.83 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -393.59% Price to Book: 0.24Contact Details: Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667 Tel: 1 781 6524500 Fax: 1 302 5313150 Website: http://www.avenuetx.com/

Q: Who are in the management team of Avenue Therapeutics, Inc.?

As of March 2022, the management team of Avenue Therapeutics, Inc. includes the following members:- Dr. Lindsay Rosenwald, who serves as the Executive Chairman of the Board.- Dr. Lucy Lu, who is the President, Chief Executive Officer, and a Director.- Dr. Jaideep Gogtay, who is a Director.- Ms. Garrett Ingram, who is a Director.- Mr. Neil Herskowitz, who is an Independent Director.- Dr. Jay Kranzler, who is also an Independent Director. This team is responsible for guiding the strategic direction and operations of the company.

Q: Is Avenue Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Avenue Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued, given its negative financial metrics, including a Price to Book Value of 0.24 and an EV to EBITDA ratio of 0.28. Additionally, the Return on Equity (ROE) is alarmingly low at -393.59%, highlighting severe profitability issues.In comparison to its peers, Avenue Therapeutics has a P/E ratio of -0.3745, while Fresh Tracks Therapeutics, Inc. has a P/E of 0.8418, indicating that Avenue is lagging behind in valuation metrics. Furthermore, Pulmatrix, Inc. shows a more negative EV to EBITDA ratio of -1.4762, suggesting that Avenue's valuation is less favorable in the context of its industry. Notably, the company's stock has underperformed significantly, with a year-to-date return of -57.50% compared to the S&P 500's 12.22%, reinforcing the notion that it is overvalued in the current market environment.

Q: Is Avenue Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Avenue Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD and KST also indicate mild bullishness. However, the weekly RSI is bearish, and the daily moving averages are mildly bearish. The Bollinger Bands show a bullish stance on the weekly but are mildly bearish on the monthly. According to Dow Theory, there is no trend on the weekly but a mild bullish trend on the monthly.In terms of performance, the stock has significantly underperformed the S&P 500 over the past year, with a return of -68.52% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands, despite some bearish signals from the RSI and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.04 k

Shareholding (Sep 2025)

FII

0.00%

Held by 1 FIIs

DII

99.72%

Held by 0 DIIs

Promoter

0.00%

How big is Avenue Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Avenue Therapeutics, Inc. has a market capitalization of 0.83 million, classifying it as a Micro Cap, with net sales of 0.00 million and a net profit of -13.71 million over the last four quarters. As of December 2024, the company has shareholder's funds of 2.80 million and total assets of 2.67 million.

View full answer

What does Avenue Therapeutics, Inc. do?

22-Jun-2025

Avenue Therapeutics, Inc. is a pharmaceutical company developing intravenous Tramadol for post-operative pain management. It has a market cap of $0.83 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Avenue Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Avenue Therapeutics, Inc.'s management team includes Dr. Lindsay Rosenwald (Executive Chairman), Dr. Lucy Lu (President and CEO), Dr. Jaideep Gogtay, Ms. Garrett Ingram, Mr. Neil Herskowitz, and Dr. Jay Kranzler (all Directors). They oversee the company's strategic direction and operations.

View full answer

Is Avenue Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Avenue Therapeutics, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 0.24, an EV to EBITDA ratio of 0.28, and a troubling ROE of -393.59%, alongside a year-to-date stock return of -57.50% compared to the S&P 500's 12.22%.

View full answer

Is Avenue Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Avenue Therapeutics, Inc. shows a mildly bullish technical trend, supported by weekly MACD and KST indicators, despite some bearish signals from the RSI and moving averages, and has significantly underperformed the S&P 500 with a return of -68.52% over the past year.

View full answer

Compare Avenue Therapeutics, Inc. with Similar Stocks

Soligenix, Inc.Fresh Tracks Therapeutics, Inc.DMK Pharmaceuticals Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 19.14% over the last 5 years

Positive results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-107.03%

Price to Book

0.45

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-76.84%

6 Months

-53.52%

1 Year

-84.28%

2 Years

-97.97%

3 Years

-84.51%

4 Years

-99.97%

5 Years

-100.0%

Avenue Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

19.14%

EBIT Growth (5y)

7.27%

EBIT to Interest (avg)

-7.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.37

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.23%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.24

EV to EBIT

0.28

EV to EBITDA

0.28

EV to Capital Employed

-2.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-393.59%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.28%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 104.17% vs -80.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "-2.80",
          "chgp": "110.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.30",
          "val2": "-7.20",
          "chgp": "104.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "211.50%",
          "val2": "0.00%",
          "chgp": "21.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.43% vs -191.67% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.30",
          "val2": "-14.50",
          "chgp": "22.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "3.90",
          "chgp": "-115.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.70",
          "val2": "-10.50",
          "chgp": "-11.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

1.40

0.00

Operating Profit (PBDIT) excl Other Income

0.30

-2.80

110.71%

Interest

0.00

Exceptional Items

0.00

0.10

-100.00%

Consolidate Net Profit

0.30

-7.20

104.17%

Operating Profit Margin (Excl OI)

211.50%

0.00%

21.15%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 104.17% vs -80.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.30

-14.50

22.07%

Interest

0.00

Exceptional Items

-0.60

3.90

-115.38%

Consolidate Net Profit

-11.70

-10.50

-11.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.43% vs -191.67% in Dec 2023

All Annual Results

Company CV

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.

Company Coordinates

Company Details

2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667

Tel: 1 781 6524500

http://www.avenuetx.com/

Registrar Details

Avenue Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Avenue Therapeutics, Inc.?

Watch in Real-Time

What does Avenue Therapeutics, Inc. do?

Who are in the management team of Avenue Therapeutics, Inc.?

Is Avenue Therapeutics, Inc. overvalued or undervalued?

Is Avenue Therapeutics, Inc. technically bullish or bearish?

Compare Avenue Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROCE of 0%

Poor long term growth as Net Sales has grown by an annual rate of 19.14% over the last 5 years

Positive results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Avenue Therapeutics, Inc.

Company Coordinates